Overview

Trial to Investigate Intensified Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Cancer

Status:
Active, not recruiting
Trial end date:
2020-10-01
Target enrollment:
Participant gender:
Summary
The aim ot the study is to investigate the efficacy and safety of two new intensified chemotherapy regimens (gemcitabine (Gem)/nab- paclitaxel (PAC), FOLFIRINOX) as neoadjuvant chemotherapy protocol in locally advanced, non-metastatic pancreatic cancer (LAPC) and consecutive conversion of the tumor to resectability.
Phase:
Phase 2
Details
Lead Sponsor:
AIO-Studien-gGmbH
Collaborators:
Celgene Corporation
ClinAssess GmbH